Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 8/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179131 | 0.80 | ULK1 (0.50) | ULK1 | |
| SCHEMBL16684845 | 0.78 | ULK1 (0.50) | ULK1PRKCQPOLBL3MBTL1KHK | |
| SCHEMBL20661198 | 0.78 | POLB (0.75) | ULK1POLB | |
| SCHEMBL18315551 | 0.75 | ENPP2 (0.48) | ULK1POLBL3MBTL1PDPK1 | |
| SCHEMBL30410367 | 0.74 | CHRM5 (0.56) | — | |
| SCHEMBL1156215 | 0.74 | PEPD (0.42) | PDPK1 | |
| SCHEMBL1247686 | 0.74 | ROCK2 (0.55) | POLB | |
| SCHEMBL23390119 | 0.73 | ULK1 (0.49) | ULK1PRKCQKHKALOX15FLT3 | |
| SCHEMBL6037575 | 0.73 | ALDH1A1 (0.52) | ULK1POLBKHKALOX15FLT3 | |
| SCHEMBL9172845 | 0.73 | ROCK2 (0.54) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | ULK1 1901/4885PRKCQ 644/4885POLB 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.